Cargando…
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer
Molecularly targeted therapies are rapidly growing with respect to their clinical development and impact on cancer treatment due to their highly selective anti-tumor action. However, many aggressive cancers such as triple-negative breast cancer (TNBC) currently lack well-defined therapeutic targets...
Autores principales: | Maric, Gordana, Rose, April AN, Annis, Matthew G, Siegel, Peter M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711880/ https://www.ncbi.nlm.nih.gov/pubmed/23874106 http://dx.doi.org/10.2147/OTT.S44906 |
Ejemplares similares
-
Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer
por: Huang, Yu-Hsiang, et al.
Publicado: (2021) -
ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties
por: Rose, April A. N., et al.
Publicado: (2010) -
THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
por: Gibbons, Erin, et al.
Publicado: (2023) -
Serum glycoprotein non-metastatic melanoma protein B (GPNMB) level as a potential biomarker for diabetes mellitus-related cataract: A cross-sectional study
por: Huo, Da, et al.
Publicado: (2023) -
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor
por: Neal, Matthew L., et al.
Publicado: (2018)